In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus.

Abstract

Mycobacterium abscessus infections are difficult to treat because of their resistance to many antibiotics. In vitro, tedizolid combined with imipenem displayed a moderate synergistic effect (fractional inhibitory concentration index, 0.41) but no bactericidal activity. Intracellularly, tedizolid 2 μg/ml (half of the MIC), corresponding to the peak serum concentration, increased the efficacy of imipenem at 8 and 32 μg/ml. Addition of avibactam and rifabutin, alone or in combination, improved the activity of the imipenem-tedizolid combination.

• Authors: Eva Le Run, Michel Arthur, Jean-Luc Mainardi
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 63 Issue 4 (04 2019) ISSN: 1098-6596 [Electronic] United States
• PMID: 30745387 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 American Society for Microbiology.

Chemical References

• Anti-Bacterial Agents
• Azabicyclo Compounds
• Oxazolidinones
• Tetrazoles
• Rifabutin
• Imipenem
• avibactam
• tedizolid
• beta-Lactamases

Topics

• Anti-Bacterial Agents (administration & dosage, pharmacology)
• Azabicyclo Compounds (pharmacology)
• Dose-Response Relationship, Drug
• Drug Synergism
• Drug Therapy, Combination
• Humans
• Imipenem (administration & dosage, pharmacology)
• Macrophages (microbiology)
• Microbial Sensitivity Tests
• Mycobacterium Infections, Nontuberculous (drug therapy)
• Mycobacterium abscessus (drug effects, genetics)
• Oxazolidinones (pharmacology)
• Rifabutin (pharmacology)
• Tetrazoles (pharmacology)
• beta-Lactamases (genetics, metabolism)